Drug Database
Back to search

Japan· JP-2190043M1025

タファミジス

A tafamidis product containing タファミジス, registered in Japan by ファイザー, on the national reimbursement list. The same ATC class is registered in 17 of our 19 countries.

On Japan’s NHI price listATC N07XX08

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedタファミジスATCN07XX08REGISTER NO.JP-2190043M1025PACKS LISTED0CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about タファミジスAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Tafamidis is registered in 17 of 19 countries.

Countries holding a registration under ATC N07XX08 (tafamidis), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 9 of them publish a price we can compare per daily dose
Search tafamidis products by name

Tafamidis · ATC N07XX08

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of tafamidis costs, country by country.

Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.082 in France to $118.78 in Switzerland — a ×1457 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Tafamidis · price per daily dose (20 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$118.78
  • FR France$0.082
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

MHLW / PMDA (Japan)
Active substance
タファミジス
Manufacturer
ファイザー
Country
Japan (JP)
ATC code
N07XX08
ATC class
Tafamidis
Defined daily dose
20 mg, O
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

18 interactions on record for tafamidis.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check tafamidis against other medicinesHow interaction checks work

Tafamidis · interactions on record

18 records

  • 2 severe
  • 16 moderate

Most severe, free to view

  • OzanimodL04AA38severe
  • OzanimodL04AE02severe
  • EltrombopagB02BX05moderate
  • LusutrombopagB02BX07moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under N07XX08

Tafamidis, as other registers publish it.

All tafamidis products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ab29d075-ae11-43eb-ae93-cdd6f61549ec
GET /v1/drugs/ab29d075-ae11-43eb-ae93-cdd6f61549ec?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "６１ｍｇ１カプセル",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "2190043M1025",
  "category": "内用薬",
  "price_yen": 32112.6,
  "generic_name": "タファミジス",
  "product_name_jp": null,
  "therapeutic_class": "2190",
  "transitional_expiry": null
}
API referenceMCP serverPlans

See everything about tafamidis.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console